iHealthScreen Inc. applies for FDA 510K Submission for iPredict™, an AI-based, software as a medical device tool to diagnosis AMD
The iPredictTM AI Eye Screening System will provide a fully automated age-related macular degeneration (AMD) screening report in less than 60 seconds.
The Korean MFDS grants IND approval for PharmAbcine’s phase I clinical trial of its novel TIE2 agonistic antibody in nAMD
PMC-403 is a first-in-class antibody that activates TIE2, a receptor specifically expressed in vascular endothelial cells. The clinical trial will take place in multiple hospitals in South Korea.
Research provides evidence for protein deletion in age and diabetes related retinal diseases
The research conducted at the Wayne State University School of Medicine implies that VCAM1 antagonism could be a promising therapeutic strategy for proliferative retinal disorders.
Adverum Biotechnologies shares nonclinical data to support Ixo-vec’s phase 2 clinical development
Data presented at the ASGCT 2023 Annual Meeting supports that Adverum’s Ixo-vec allows for lower dose administration with improved inflammation profile.
Phase 2 study of ABVC BioPharma Vitargus® receives ethical approval at Sydney Eye Hospital in Australia
Early clinical studies indicate that Vitargus® has unique properties that could eliminate the need for patients to remain face-down after retinal detachment and vitreous hemorrhage surgery.
Adverum Biotechnologies presents gene therapy data and introduces an intravitreal gene therapy program for geographic atrophy
The company made these announcements at the American Society of Gene & Cell Therapy (ASGCT) 2023 Annual Meeting in Los Angeles, California.
EyePoint Pharmaceuticals sells YUTIQ® to Alimera Sciences, Inc. for $82.5 million (USD) plus royalties
The sale of YUTIQ® will empower EyePoint Pharmaceuticals to continue to advance its pipeline of therapeutics through the company's upcoming clinical trials.
Ray Therapeutics closes Series A financing to advance therapeutics in clinical development
The company received $100 million (USD) in this financing round from several investment partners as they generate new optogenetic therapeutics for blinding diseases.
Research shows drug could prevent vision loss in premature newborns
Researchers at the Medical College of Georgia have shown in an animal model of retinopathy of prematurity that the small molecule K604 can block the development of leaky, obstructive blood vessels in the retina, tamp down inflammation and enable more normal blood vessel growth.
Aviceda Therapeutics appoints Patrick Johnson to its board of directors
Aviceda Therapeutics appoints Patrick Johnson, a strategic pharmaceutical executive, to its board of directors.
AI-based eye disease detection startup, Eyetelligence raises $12 million USD from investors
Eyetelligence will offer non-invasive point-of-care technology to diagnose a range of diseases, including diabetic retinopathy and age-related macular degeneration, with AI algorithmic retinal image analysis.
Study shows non-random association between missing electronic health record data regarding the severity of diabetic retinopathy
A study by Verana Health shows how de-identified real-world data (RWD) from electronic health records (EHRs) in medical registries can allow for a deeper understanding of data trends, patterns, or gaps.
FDA clears C. Light to market retinal eye movement monitor, Retitrack™
This medical device is the first retinal eye-movement monitor for non-invasive, objective clinical assessments.
Stress resilience-enhancing drugs may provide new therapeutics to treat AMD, DR, and RP
The study results show the potential of SREDs to treat progressive, chronic retina conditions including age-related macular degeneration (AMD), diabetic retinopathy (DR), and retinitis pigmentosa (RP).
New York ophthalmologist begins syfovre treatment for geographic atrophy in patients with dry AMD
The treatment is designed to slow the rate of degeneration of retinal cells, slowing the progression of geographic atrophy.
The NOD audit provides data and insights for the management for neovascular age-related macular degeneration
Researchers compile data from around 18,000 patients to provide a comprehensive understanding of the current state of nAMD treatment in the UK.
Analysis of human eye tissue from unique biorepository may lead to development of therapeutics for AMD
Researchers collaborate to study AMD through database of donor eye tissue to provide new data for study and future treatment targeting.
Abu Dhabi Health Services Company launches clinic to address uveitis in children
New clinic dedicated to treating pediatric uveitis opens in the UAE.
New research identifies genes related to oxidative stress and AMD
Researchers in Australia have identified genes that play a role in oxidative stress and aging in the macula.
Endogena Therapeutics completes enrollment early for its Phase 1/2a trial of EA-2353 for retinitis pigmentosa
Endogena Therapeutics Inc. has completed patient enrollment ahead of schedule with a cohort of 14 patients with RP due to any pathologic genetic mutation across 5 US sites.
UNITY Biotechnology announces results from Phase 2 BEHOLD study of patients with DME
A single injection of UBX1325 led to a statistically significant and clinically meaningful improvement in Best Corrected Visual Acuity (BCVA) of +6.2 ETDRS letters from baseline at 48 weeks.
ARVO 2023: Valitor’s Presentation at ARVO 2023 details preclinical Data on its Anti-VEGF biologic in development for durable treatment of wet AMD
VLTR-557, Valitor's long-acting anti-VEGF biologic in development for durable wet age-related macular degeneration (AMD) treatment, showed that a single intravitreal (ITV) injection has potential to maintain clinical efficacy for more than six months.
Stoke Therapeutics Receives Authorization to Initiate a Phase 1/2 Study of STK-002 for ADOA in the UK
Stoke Therapeutics, Inc. received authorization to initiate a UK-based Phase 1/2 study of STK-002, a treatment of autosomal dominant optic atrophy (ADOA), for which there is currently no approved treatments.
Multiomics eye study identifies genes with age-related macular degeneration risks
A team of researchers used gene expression, epigenetic, and gene regulation analyses to discover genes, pathways, and regulatory features relevant to age-related macular degeneration (AMD).
RetinAI and Boehringer Ingelheim partner to further AI identification and treatment of geographic atrophy
RetinAI announced their new partnership with Boehringer Ingelheim with the goal to improve patient outcomes in geographic atrophy (GA) by combining their respective expertise in artificial intelligence and retinal disease research.
Published data demonstrates the effects of PL8331 in mouse models of retinal disease
Palatin Technologies, Inc. announced manuscript publication that summarizes data demonstrating the effects of PL8331 in two mouse models of retinal disease, experimental autoimmune uveoretinitis and diabetic retinopathy.
Complement Therapeutics completes Series A funding with €72 Million, a step toward new therapies for GA and dry-AMD
Complement Therapeutics GmbH secured financing to continue the development and complete a Phase Ib clinical proof of concept of its lead product CTx001, an AAV gene therapy for the treatment of GA secondary to dry-AMD.
Aviceda announces FDA clearance of the IND application for AVD-104 enabling initiation of phase 2 clinical trials
Aviceda Therapeutics announced that the FDA has cleared the Investigational New Drug application for AVD-104, enabling the company to proceed with initiation of Phase 2 clinical trials.
Early real-world study concludes brolucizumab is a viable alternative for select patients with nAMD
Study results see brolucizumab as a viable treatment for patients with neovascular age-related macular degeneration (nAMD) refractory to other anti-VEGF drugs.
FDA grants fast track designation for KPI-012 by Kala Pharmaceuticals
Kala Pharmaceuticals KPI-012 receives FDA Fast Track designation as treatment for PCED with potential to treat retinitis pigmentosa and Stargardt disease.
2 Clarke Drive Cranbury, NJ 08512